

# Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

<https://marketpublishers.com/r/IE849E21F187EN.html>

Date: October 2021

Pages: 210

Price: US\$ 3,750.00 (Single User License)

ID: IE849E21F187EN

## Abstracts

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Immunotherapy Drugs Market Report

The global immunotherapy drugs market was valued at USD 169.47 billion in 2020 and is expected to reach USD 326.36 billion by 2026, growing at a CAGR of 11.54%.

The major factor responsible for growth in the immunotherapy drugs industry is an increase in demand for outsourcing the manufacturing of immunotherapy drugs by several biopharmaceuticals and biotechnological companies and resistance against conventional treatments. Major key players and other prominent vendors engaged in the immunotherapy drugs domain are constantly focussing on product launches, product approvals, R&D activities, and expanding their organic growth.

The following factors are likely to contribute to the growth of the global immunotherapy market during the forecast period:

Next-generation immunotherapies

COVID-19 as a catalyst

Investment in research & development activities

Mergers & acquisitions

Surge of CAR-T therapies

## KEY HIGHLIGHTS

The emergence of various diseases in developing countries is propelling the usage of monoclonal antibodies, demanding the introduction of newer immunotherapies and creating opportunities for the market.

Cancer immunotherapy drugs revolutionized in cancer therapies that have begun to shift curve of cancer patients by increasing their lifespan.

The increasing immunotherapy drugs pipeline coupled with the emergence of the pandemic has scaled up the production of medicines.

By product, the adoptive cell therapy segment is expected to witness absolute growth of 1280% during the forecast period.

The recent trend of mergers and acquisitions is boosting the growth of the immunotherapy drugs industry. For instance, Bristol-Myers Squibb's one of most recent and high-value transactions was the acquisition of Celgene in January 2018.

The study considers a detailed scenario of the present global immunotherapy drugs market and its market dynamics for the period 2021-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

## GLOBAL IMMUNOTHERAPY MARKET SEGMENTATION

This research report includes a detailed segmentation by

Product

Application

Geography

## GLOBAL IMMUNOTHERAPY MARKET SEGMENTS

The monoclonal antibody segment accounted for the high share of 72.6% of the global immunotherapy drugs market in 2020. Significant advances in the field, notably, and the unprecedented results obtained using monoclonal antibodies that attach themselves to lymphocytes. This restores their functioning toward tumor cell and thus create a defense for the body against cancer.

The autoimmune diseases segment accounted for the highest market share in 2020. It is expected to post an incremental growth of USD 23.95 billion with 33% absolute growth during the forecast period. The segment's growth is attributed to the increase in the prevalence of immune-mediated inflammatory diseases (IMIDs), including autoimmune and auto-inflammatory diseases.

In 2020, the cancer segment accounted for the highest market share of 45.33%. Immunotherapies in oncology have been widely popularized by developing curative therapies, such as CAR T-cell. However, developing personalized therapies such as CAR T-cell to treat various types of cancers may pose significant challenges, such as educating medical personnel regarding the procedures and creating a convenient process for engineering T-cells of the patients and infusing them.

## Segmentation by Product

Monoclonal Antibodies

Immune System Modulators

Car T-Cell Therapies

Others

## Segmentation by Application

Cancer

Auto Immune & Inflammatory Disease

Others

## GEOGRAPHICAL ANALYSIS

**North America:** North America has the highest share among all the regions and is likely to witness an absolute growth of around 105% during the forecast period. The rise in the immunotherapy drugs industry is primarily attributable to the increasing incidence rates of various types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, and leukemia, etc.

**Europe:** Europeans represent about one-tenth of the global population, yet one in four of all cancer diagnoses occur in this region. This region is likely to witness an absolute growth of around 84% during the forecast period.

**APAC:** APAC is witnessing growing demand mainly due to a large and growing population. In APAC, various opportunities associated with the growth of the cancer immunotherapy drugs market are increasing, and government initiatives will further improve the healthcare sector.

## Segmentation by Geography

### North America

US

Canada

### Europe

Germany

France

UK

Italy

Spain

## APAC

China

India

Japan

Australia

South Korea

## Latin America

Brazil

Mexico

Argentina

## Middle East & Africa

South Africa

Saudi Arabia

Turkey

## VENDOR ANALYSIS

The major vendors such as F. Hoffmann-La Roche, Bristol Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline, Novartis, AstraZeneca, and Janssen Pharmaceuticals Inc.

Bristol Myers Squibb (BMS) is a biopharmaceutical company that is helping – outpatients in succeeding ailments by delivering innovative products. It has owned innovative drugs such as OPDIVO Immunotherapy Drugs for a wider

range of diseases.

Market competitiveness is expected to increase during the forecast period as the vendors constantly focus on expanding their product portfolios.

### Key Vendors

F. Hoffmann-La Roche

Bristol Myers Squibb Company

Merck & Co., Inc.

GlaxoSmithKline

Novartis

AstraZeneca

Janssen Pharmaceuticals, Inc.

### Other Prominent Vendors

AbbVie

Alexion Pharmaceuticals

Amgen

Bayer

Dendreon

Dynavax

Eli Lilly and Company

Elusys Therapeutics, Inc

Gilead Sciences, Inc

NBE Therapeutics

Pfizer, Inc

Sanofi

Seagen Inc.

Teva pharmaceuticals

#### KEY QUESTIONS ANSWERED:

1. How big is the immunotherapy drugs market?
2. What are the products segmentation in the immunotherapy drugs market?
3. Which region has the highest growth rate for the immunotherapy drugs industry?
4. What are the latest trends in the global immunotherapy drugs market?
5. What is the impact of COVID-19 on the immunotherapy drugs market?
6. Who are the prominent players in the global immunotherapy drugs market?
7. Which countries are the major contributor for Cancer Immunotherapy Drugs Market in APAC?

## Contents

### **1 RESEARCH METHODOLOGY**

### **2 RESEARCH OBJECTIVES**

### **3 RESEARCH PROCESS**

### **4 SCOPE & COVERAGE**

#### 4.1 Market Definition

##### 4.1.1 Inclusions

##### 4.1.2 Exclusions

##### 4.1.3 Market Estimation Caveats

#### 4.2 Base Year

#### 4.3 Scope of the Study

##### 4.3.1 Market Segmentation by Geography

##### 4.3.2 Market Segmentation by Product

##### 4.3.3 Market Segmentation by Application

### **5 REPORT ASSUMPTIONS & CAVEATS**

#### 5.1 Key Caveats

#### 5.2 Currency Conversion

#### 5.3 Market Derivation

### **6 MARKET AT A GLANCE**

### **7 INTRODUCTION**

#### 7.1 Overview

### **8 MARKET OPPORTUNITIES & TRENDS**

#### 8.1 Launch of Next-Generation Immunotherapies

#### 8.2 COVID-19 as Growth Catalyst

#### 8.3 Investment in R&D Activities

#### 8.4 Mergers & Acquisitions



## **9 MARKET GROWTH ENABLERS**

- 9.1 Prevalence of Cancer & Autoimmune Diseases
- 9.2 Approval of Novel Immunotherapy Drugs
- 9.3 Surge in Adoption of Car T-Cell Therapies

## **10 MARKET RESTRAINTS**

- 10.1 Expensive Nature of Immunotherapy
- 10.2 Personalized Approach Through Biomarkers
- 10.3 Time-Consuming Production Cycle

## **11 MARKET LANDSCAPE**

- 11.1 Market Overview
- 11.2 Market Size & Forecast
  - 11.2.1 Geographic Insights
  - 11.2.2 Application Insights
  - 11.2.3 Product Insights
- 11.3 Impact of COVID-19 on Immunotherapy Drugs
- 11.4 Porter's Five Forces Analysis
  - 11.4.1 Threat of New Entrants
  - 11.4.2 Bargaining Power of Suppliers
  - 11.4.3 Bargaining Power of Buyers
  - 11.4.4 Threat of Substitutes
  - 11.4.5 Competitive Rivalry

## **12 PRODUCT**

- 12.1 Market Snapshot & Growth Engine
- 12.2 Market Overview
- 12.3 Monoclonal Antibody
  - 12.3.1 Market Overview
  - 12.3.2 Market Size & Forecast
- 12.4 Immune System Modulators
  - 12.4.1 Market Overview
  - 12.4.2 Market Size & Forecast
- 12.5 Car T-Cell Therapy
  - 12.5.1 Market overview

- 12.5.2 Market Size & Forecast
- 12.6 Others
  - 12.6.1 Market overview
  - 12.6.2 Market Size & Forecast

## **13 APPLICATION**

- 13.1 Market Snapshot & Growth Engine
- 13.2 Market Overview
- 13.3 Cancer
  - 13.3.1 Market overview
  - 13.3.2 Market Size & Forecast
- 13.4 Autoimmune & Inflammatory Diseases
  - 13.4.1 Market overview
  - 13.4.2 Market Size & Forecast
- 13.5 Others
  - 13.5.1 Market overview
  - 13.5.2 Market Size & Forecast

## **14 GEOGRAPHY**

- 14.1 Market Snapshot & Growth Engine
- 14.2 Geographic Overview

## **15 NORTH AMERICA**

- 15.1 Market Overview
- 15.2 Market Size & Forecast
- 15.3 Key Countries
  - 15.3.1 US: Market Size & Forecast
  - 15.3.2 Canada: Market Size & Forecast

## **16 EUROPE**

- 16.1 Market Overview
- 16.2 Market Size & Forecast
- 16.3 Key Countries
  - 16.3.1 Germany: Market Size & Forecast
  - 16.3.2 UK: Market Size & Forecast

16.3.3 France: Market Size & Forecast

16.3.4 Italy: Market Size & Forecast

16.3.5 Spain: Market Size & Forecast

## **17 ASIA PACIFIC**

17.1 Market Overview

17.2 Market Size & Forecast

17.3 Key Countries

17.3.1 China: Market Size & Forecast

17.3.2 India: Market Size & Forecast

17.3.3 Japan: Market Size & Forecast

17.3.4 Australia: Market Size & Forecast

17.3.5 South Korea: Market Size & Forecast

## **18 LATIN AMERICA**

18.1 Market Overview

18.2 Market Size & Forecast

18.3 Key Countries

18.3.1 Brazil: Market Size & Forecast

18.3.2 Mexico: Market Size & Forecast

18.3.3 Argentina: Market Size & Forecast

## **19 MIDDLE EAST & AFRICA**

19.1 Market Overview

19.2 Market Size & Forecast

19.3 Key Countries

19.3.1 South Africa: Market Size & Forecast

19.3.2 Saudi Arabia: Market Size & Forecast

19.3.3 Turkey: Market & Forecast

## **20 COMPETITIVE LANDSCAPE**

20.1 Competition Overview

20.2 Market Share Analysis

20.2.1 F. Hoffmann-La Roche AG

20.2.2 Bristol Myers Squibb

- 20.2.3 Merck & Co., Inc.
- 20.2.4 GlaxoSmithKline
- 20.2.5 Novartis
- 20.2.6 AstraZeneca
- 20.2.7 Janssen Pharmaceuticals

## **21 KEY COMPANY PROFILES**

- 21.1 F. Hoffmann-La Roche
  - 21.1.1 Business Overview
  - 21.1.2 Product Offerings
  - 21.1.3 Key Strategies
  - 21.1.4 Key Strengths
  - 21.1.5 Key Opportunities
- 21.2 Bristol-Myers Squibb Company
  - 21.2.1 Business Overview
  - 21.2.2 Product Offerings
  - 21.2.3 Key Strategies
  - 21.2.4 Key Strengths
  - 21.2.5 Key Opportunities
- 21.3 Merck & Co., Inc.
  - 21.3.1 Business Overview
  - 21.3.2 Product Offerings
  - 21.3.3 Key Strategies
  - 21.3.4 Key Strengths
  - 21.3.5 Key Opportunities
- 21.4 GlaxoSmithKline
  - 21.4.1 Business Overview
  - 21.4.2 Product Offerings
  - 21.4.3 Key Strategies
  - 21.4.4 Key Strengths
  - 21.4.5 Key Opportunities
- 21.5 Novartis
  - 21.5.1 Business Overview
  - 21.5.2 Product Offerings
  - 21.5.3 Key Strategies
  - 21.5.4 Key Strengths
  - 21.5.5 Key Opportunities
- 21.6 Astrazeneca

- 21.6.1 Business Overview
- 21.6.2 Product Offerings
- 21.6.3 Key Strategies
- 21.6.4 Key Strengths
- 21.6.5 Key Opportunities
- 21.7 Janssen Pharmaceuticals, Inc.
  - 21.7.1 Business Overview
  - 21.7.2 Product Offerings
  - 21.7.3 Key Strategies
  - 21.7.4 Key Strengths
  - 21.7.5 Key Opportunities

## **22 OTHER PROMINENT VENDORS**

- 22.1 Abbvie
  - 22.1.1 Business Overview
  - 22.1.2 Product Offerings
- 22.2 Alexion Pharmaceuticals
  - 22.2.1 Business Overview
  - 22.2.2 Product Offerings
- 22.3 Amgen
  - 22.3.1 Business Overview
  - 22.3.2 Product Offerings
- 22.4 Bayer
  - 22.4.1 Business Overview
  - 22.4.2 Product Offerings
- 22.5 Dendreon
  - 22.5.1 Business Overview
  - 22.5.2 Product Offerings
- 22.6 Dynavax
  - 22.6.1 Business Overview
  - 22.6.2 Product Offerings
- 22.7 Eli Lilly & Company
  - 22.7.1 Business Overview
  - 22.7.2 Product Offerings
- 22.8 Elusys Therapeutics, Inc.
  - 22.8.1 Business Overview
  - 22.8.2 Product Offerings
- 22.9 Gilead Sciences, Inc.

- 22.9.1 Business Overview
- 22.9.2 Product Offerings
- 22.10 NBE Therapeutics
  - 22.10.1 Business Overview
- 22.11 Pfizer, Inc.
  - 22.11.1 Business Overview
  - 22.11.2 Product Offerings
- 22.12 Sanofi
  - 22.12.1 Business Overview
  - 22.12.2 Product Offerings
- 22.13 Seagen Inc.
  - 22.13.1 Business Overview
  - 22.13.2 Product Offerings
- 22.14 Teva Pharmaceuticals
  - 22.14.1 Business Overview
  - 22.14.2 Product Offerings

## **23 REPORT SUMMARY**

- 23.1 Key Takeaways
- 23.2 Strategic Recommendations

## **24 QUANTITATIVE SUMMARY**

- 24.1 Market by Geography
- 24.2 Market by Product
- 24.3 Market by Application

## **25 APPENDIX**

- 25.1 Abbreviations

## List Of Exhibits

### LIST OF EXHIBITS

- Exhibit 1 Segmentation of Global Immunotherapy Drugs Market
- Exhibit 2 Market Size Calculation Approach 2020
- Exhibit 3 Impact of Launch of Next-Generation Immunotherapies
- Exhibit 4 Impact of COVID-19 as Growth Catalyst
- Exhibit 5 Impact of Investment in R&D Activities
- Exhibit 6 Impact of Mergers & Acquisitions
- Exhibit 7 Impact of Prevalence of Cancer & Autoimmune Diseases
- Exhibit 8 Impact of Approval of Novel Immunotherapy Drugs
- Exhibit 9 Impact of Surge in Adoption of CAR T-cell Therapies
- Exhibit 10 Number of CAR T-cell Therapies in Clinical Trials (January 2018)
- Exhibit 11 Major Vendors Engaged in CAR T-cell Therapy Development
- Exhibit 12 Approved CAR T-cell Therapies
- Exhibit 13 Impact of Expensive Nature of Immunotherapy
- Exhibit 14 Impact of Personalized Approach through Biomarkers
- Exhibit 15 Impact of Time-consuming Production Cycle
- Exhibit 16 Global Immunotherapy Drugs Market 2020–2026 (\$ billion)
- Exhibit 17 Five Forces Analysis 2020
- Exhibit 18 Incremental Growth by Product Segment 2020 & 2026
- Exhibit 19 Global Monoclonal Antibody Market 2020–2026 (\$ billion)
- Exhibit 20 Global Immunomodulator Market 2020–2026 (\$ billion)
- Exhibit 21 Global Funding for Development of Cell Therapy 2017–2020 (\$ billion)
- Exhibit 22 Revenues of Kymriah and Yescarta (\$ million)
- Exhibit 23 Global CAR T-cell Therapy Market 2020–2026 (\$ billion)
- Exhibit 24 Global Other Immunotherapy Drugs Market 2020–2026 (\$ billion)
- Exhibit 25 Incremental Growth by Application Segment 2020 & 2026
- Exhibit 26 Number of Products in Clinical Trials in Oncology Application
- Exhibit 27 Global Cancer Immunotherapy Drugs Market 2020-2026 (\$ billion)
- Exhibit 28 Global Autoimmune & Inflammatory Diseases Immunotherapy Drugs Market 2020-2026 (\$ billion)
- Exhibit 29 Global Other Immunotherapy Applications Market 2020-2026 (\$ billion)
- Exhibit 30 Incremental Growth by Geography 2020 & 2026
- Exhibit 31 New Cancer Cases Reported in North America 2020
- Exhibit 32 Market Share of Major Countries in North America
- Exhibit 33 North America Immunotherapy Drugs Market 2020–2026 (\$ billion)
- Exhibit 34 Incremental Growth in North America 2020 & 2026

- Exhibit 35 US Immunotherapy Drugs Market 2020–2026 (\$ billion)
- Exhibit 36 Immunotherapy Drugs Market in Canada 2020–2026 (\$ billion)
- Exhibit 37 Market Share of Major Countries in Europe
- Exhibit 38 Europe Immunotherapy Drugs Market 2020–2026 (\$ billion)
- Exhibit 39 Incremental Growth in Europe 2020 & 2026
- Exhibit 40 Immunotherapy Drugs Market in Germany 2020–2026 (\$ billion)
- Exhibit 41 Estimated Number of People Living with Cancer by 2030 (million)
- Exhibit 42 UK Immunotherapy Drugs Market 2020–2026 (\$ billion)
- Exhibit 43 Immunotherapy Drugs Market in France 2020–2026 (\$ billion)
- Exhibit 44 Per Capita Healthcare Expenditure in Italy between 2016 & 2018 (\$)
- Exhibit 45 Immunotherapy drugs Market in Italy 2020–2026 (\$ billion)
- Exhibit 46 Immunotherapy Drugs Market in Spain 2020–2026 (\$ billion)
- Exhibit 47 Market Share of Major Countries in APAC
- Exhibit 48 APAC Immunotherapy drugs Market 2020–2026 (\$ billion)
- Exhibit 49 Incremental Growth in APAC 2020 & 2026
- Exhibit 50 Number of new Types of Cancer Cases reported in China (2020)
- Exhibit 51 Immunotherapy Drugs Market in China 2020–2026 (billion)
- Exhibit 52 Immunotherapy Drugs Market in India 2020–2026 (\$ billion)
- Exhibit 53 Immunotherapy Drugs Market in Japan 2020–2026 (\$ billion)
- Exhibit 54 Immunotherapy Drugs Market in Australia 2020–2026 (\$ billion)
- Exhibit 55 Number of New Types of Cancer Cases Reported in Australia (2020)
- Exhibit 56 Number of New Types of Cancers in South Korea (2020)
- Exhibit 57 Immunotherapy Drugs Market in South Korea 2020–2026 (\$ billion)
- Exhibit 58 New Types of Cancer Cases Reported in Latin America (2020)
- Exhibit 59 Market Share of Major Countries in Latin America
- Exhibit 60 Latin America Immunotherapy Drugs Market 2020–2026 (\$ billion)
- Exhibit 61 Incremental Growth in Latin America 2020 & 2026
- Exhibit 62 Immunotherapy Drugs Market in Brazil 2020–2026 (\$ billion)
- Exhibit 63 Number of New Types of Cancer Cases Reported in Mexico (2020)
- Exhibit 64 Immunotherapy Drugs Market in Mexico 2020–2026 (\$ billion)
- Exhibit 65 Immunotherapy Drugs Market in Argentina 2020–2026 (\$ billion)
- Exhibit 66 Market Share of Major countries in MEA
- Exhibit 67 MEA Immunotherapy Drugs Market 2020–2026 (\$ billion)
- Exhibit 68 Incremental Growth in Middle East & Africa 2020 & 2026
- Exhibit 69 Cancer Cases in Key Countries across MEA 2020
- Exhibit 70 Immunotherapy Drugs Market in South Africa 2020–2026 (\$ billion)
- Exhibit 71 Immunotherapy Drugs Market in Saudi Arabia 2020–2026 (\$ billion)
- Exhibit 72 Number of New Cancer Cases Reported in Turkey (2020)
- Exhibit 73 Immunotherapy Drugs Market in Turkey 2020–2026 (\$ billion)



Exhibit 74 Global Immunotherapy Drugs Market by Product 2020–2026

Exhibit 75 Global Immunotherapy Drugs Market by Application 2020–2026

## List Of Tables

### LIST OF TABLES

Table 1	Key Caveats
Table 2	Currency Conversion 2013–2020
Table 3	Major Mergers & Acquisitions
Table 4	Major Approved Immunotherapy Drugs
Table 5	CAR T-cell Investigational Products
Table 6	Cost of Kymriah in Different Regions
Table 7	CAGR & Revenue of Approved CAR T-cell Therapies 2018–2020 (\$ million)
Table 8	CAGR & Revenue of Other Approved Therapies 2018–2020 (\$ million)
Table 9	CAR-T Therapies Approved in Japan Region
Table 10	F. Hoffmann-La Roche: Major Product Offerings
Table 11	Bristol Myers Squibb: Major Product Offerings
Table 12	Merck & Co., Inc.: Major Product Offerings
Table 13	GlaxoSmithKline: Major Product Offerings
Table 14	Novartis: Major Product Offerings
Table 15	AstraZeneca: Major Product Offerings
Table 16	Janssen Pharmaceuticals, Inc.: Major Product Offerings
Table 17	AbbVie: Major Product Offerings
Table 18	Alexion Pharmaceuticals: Major Product Offerings
Table 19	Amgen: Major Product Offerings
Table 20	Bayer: Major Product Offerings
Table 21	Dendreon: Major Product Offerings
Table 22	Dynavax: Major Product Offerings
Table 23	Eli Lilly & Company: Major Product Offerings
Table 24	Elusys Therapeutics, Inc.: Major Product Offerings
Table 25	Gilead Sciences, Inc.: Major Product Offerings
Table 26	Pfizer, Inc.: Major Product Offerings
Table 27	Sanofi: Major Product Offerings
Table 28	Seagen Inc.: Major Product Offerings
Table 29	Teva Pharmaceuticals: Major Product Offerings
Table 30	Global Immunotherapy Drugs Market by 2020–2026 (\$ billion) (Geography)
Table 31	North America Immunotherapy Drugs Market 2020–2026 (%)
Table 32	Europe Immunotherapy Drugs Market 2020–2026 (%)
Table 33	APAC Immunotherapy Drugs Market 2020–2026 (%)
Table 34	Latin America Immunotherapy Drugs Market 2020–2026 (%)
Table 35	MEA Immunotherapy Drugs Market 2020–2026 (%)

## I would like to order

Product name: Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

Product link: <https://marketpublishers.com/r/IE849E21F187EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IE849E21F187EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970